| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5607942 | BAYER HLTHCARE | 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives |
Mar, 2014
(10 years ago) | |
| US5849752 | BAYER HLTHCARE | Crystal modification of CDCH a process for its preparation and pharmaceutical formulations comprising this modification |
Dec, 2016
(7 years ago) | |
| US6610327 | BAYER HLTHCARE | Pharmaceutical moxifloxacin preparation |
Oct, 2019
(4 years ago) | |
Avelox is owned by Bayer Hlthcare.
Avelox contains Moxifloxacin Hydrochloride.
Avelox has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Avelox are:
- US5607942
- US5849752
- US6610327
Avelox was authorised for market use on 10 December, 1999.
Avelox is available in tablet;oral dosage forms.
Avelox can be used as method of combating bacteria in a patient.
The generics of Avelox are possible to be released after 29 October, 2019.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-185) | Sep 27, 2019 |
Drugs and Companies using MOXIFLOXACIN HYDROCHLORIDE ingredient
Market Authorisation Date: 10 December, 1999
Treatment: Method of combating bacteria in a patient
Dosage: TABLET;ORAL
How can I launch a generic of AVELOX before it's drug patent expiration?
More Information on Dosage
AVELOX family patents
